Literature DB >> 27338086

Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate.

Monique E Hinchcliff1, Jon Lomasney2, Julie A Johnson3, John Varga3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27338086      PMCID： PMC5854093          DOI： 10.1093/rheumatology/kew245

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  8 in total

Review 1.  Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.

Authors:  Vasiliki-Kalliopi Bournia; Konstantinos Evangelou; Petros P Sfikakis
Journal:  Semin Arthritis Rheum       Date:  2012-07-11       Impact factor: 5.532

2.  A novel physiological function for platelet-derived growth factor-BB in rat dermis.

Authors:  S A Rodt; K Ahlén; A Berg; K Rubin; R K Reed
Journal:  J Physiol       Date:  1996-08-15       Impact factor: 5.182

3.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.

Authors:  K Pietras; A Ostman; M Sjöquist; E Buchdunger; R K Reed; C H Heldin; K Rubin
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

4.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

5.  Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis.

Authors:  V S Rajkumar; C Sundberg; D J Abraham; K Rubin; C M Black
Journal:  Arthritis Rheum       Date:  1999-05

6.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

7.  Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.

Authors:  Vishnu Chintalgattu; Meredith L Rees; James C Culver; Aditya Goel; Tilahu Jiffar; Jianhu Zhang; Kenneth Dunner; Shibani Pati; James A Bankson; Renata Pasqualini; Wadih Arap; Nathan S Bryan; Heinrich Taegtmeyer; Robert R Langley; Hui Yao; Michael E Kupferman; Mark L Entman; Mary E Dickinson; Aarif Y Khakoo
Journal:  Sci Transl Med       Date:  2013-05-29       Impact factor: 17.956

8.  Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Authors:  Jessica K Gordon; Viktor Martyanov; Cynthia Magro; Horatio F Wildman; Tammara A Wood; Wei-Ti Huang; Mary K Crow; Michael L Whitfield; Robert F Spiera
Journal:  Arthritis Res Ther       Date:  2015-08-18       Impact factor: 5.156
  8 in total
  1 in total

1.  Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy.

Authors:  Efthymia Pappa; Marina Gkeka; Ifigeneia Kiki; Pagona Gourna; Constantinos Christopoulos
Journal:  Cureus       Date:  2021-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.